Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026)
Beam Therapeutics (BEAM) reported Income from Continuing Operations of 97348000.0 for Q1 2026, up 11.03% year-over-year from 87673774.08 in Q1 2025, and down 139.85% on a QoQ basis from 244297000.0 in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of Income from Continuing Operations data on file, last reported at 97348000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 11.03% year-over-year to 97348000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 68070000.0 (up 82.43% YoY) and the FY2025 annual result came in at 79992000.0, up 78.77% from the prior year.
- Income from Continuing Operations eased to 97348000.0 in Q1 2026 per BEAM's latest filing, from 244297000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 244297000.0 in Q4 2025 and bottomed at 112728000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 90354000.0 (2024), against an average of 55931588.24.
- The widest annual swing landed in 2022, when Income from Continuing Operations plunged 199.01%; it then jumped 472.18% in 2023.
- Tracing BEAM's Income from Continuing Operations over 5 years: stood at 38359000.0 in 2022, then jumped by 472.18% to 142763000.0 in 2023, then slumped by 163.29% to 90354000.0 in 2024, then soared by 370.38% to 244297000.0 in 2025, then slumped by 139.85% to 97348000.0 in 2026.
- Per Business Quant, the three latest BEAM Income from Continuing Operations figures stand at 97348000.0 (Q1 2026), 244297000.0 (Q4 2025), and 112728000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | -97.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.35 Mn |
| Dec 31, 2025 | 244.30 Mn |
| Sep 30, 2025 | -112.73 Mn |
| Jun 30, 2025 | -102.29 Mn |
| Mar 31, 2025 | -109.42 Mn |
| Dec 31, 2024 | -90.35 Mn |
| Sep 30, 2024 | -96.67 Mn |
| Jun 30, 2024 | -91.05 Mn |
| Mar 31, 2024 | -92.28 Mn |
| Dec 31, 2023 | 142.76 Mn |
| Sep 30, 2023 | -96.09 Mn |
| Jun 30, 2023 | -82.78 Mn |
| Mar 31, 2023 | -88.97 Mn |
| Dec 31, 2022 | -38.36 Mn |
| Sep 30, 2022 | -84.08 Mn |
| Jun 30, 2022 | -79.91 Mn |
| Mar 31, 2022 | -75.58 Mn |
| Dec 31, 2021 | -64.71 Mn |
| Sep 30, 2021 | -28.12 Mn |
| Jun 30, 2021 | -59.03 Mn |
| Mar 31, 2021 | -200.39 Mn |
| Dec 31, 2020 | -40.76 Mn |
| Sep 30, 2020 | -37.15 Mn |
| Jun 30, 2020 | -26.04 Mn |
| Mar 31, 2020 | -27.76 Mn |
| Dec 31, 2019 | -26.05 Mn |
| Sep 30, 2019 | -17.41 Mn |
| Jun 30, 2019 | -16.86 Mn |
| Mar 31, 2019 | -12.61 Mn |